527 related articles for article (PubMed ID: 9485094)
1. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
[TBL] [Abstract][Full Text] [Related]
2. Decreased beta-isomerization of the C-terminal telopeptide of type I collagen alpha 1 chain in Paget's disease of bone.
Garnero P; Fledelius C; Gineyts E; Serre CM; Vignot E; Delmas PD
J Bone Miner Res; 1997 Sep; 12(9):1407-15. PubMed ID: 9286756
[TBL] [Abstract][Full Text] [Related]
3. Effect of surgical menopause and Paget's disease of bone on the isomerization of type I collagen carboxyterminal telopeptide: evolution after antiresorptive therapy.
Peris P; Alvarez L; Monegal A; Guañabens N; Durán M; Echevarría M; Ros I; Ballesta AM; Muñoz-Gómez J
J Bone Miner Metab; 2002; 20(2):116-20. PubMed ID: 11862534
[TBL] [Abstract][Full Text] [Related]
4. Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone.
Alexandersen P; Peris P; Guañabens N; Byrjalsen I; Alvarez L; Solberg H; Cloos PA
J Bone Miner Res; 2005 Apr; 20(4):588-95. PubMed ID: 15765177
[TBL] [Abstract][Full Text] [Related]
5. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
[TBL] [Abstract][Full Text] [Related]
6. Investigation of bone disease using isomerized and racemized fragments of type I collagen.
Cloos PA; Fledelius C; Christgau S; Christiansen C; Engsig M; Delmas P; Body JJ; Garnero P
Calcif Tissue Int; 2003 Jan; 72(1):8-17. PubMed ID: 12384813
[TBL] [Abstract][Full Text] [Related]
7. Biochemical assessment of Paget's disease of bone.
Shankar S; Hosking DJ
J Bone Miner Res; 2006 Dec; 21 Suppl 2():P22-7. PubMed ID: 17229003
[TBL] [Abstract][Full Text] [Related]
8. The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget's disease of bone.
Garnero P; Christgau S; Delmas PD
Bone; 2001 May; 28(5):461-4. PubMed ID: 11344044
[TBL] [Abstract][Full Text] [Related]
9. Bone turnover and type I collagen C-telopeptide isomerization in adult osteogenesis imperfecta: associations with collagen gene mutations.
Garnero P; Schott AM; Prockop D; Chevrel G
Bone; 2009 Mar; 44(3):461-6. PubMed ID: 19071236
[TBL] [Abstract][Full Text] [Related]
10. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease.
Alvarez L; Guañabens N; Peris P; Monegal A; Bedini JL; Deulofeu R; Martinez de Osaba MJ; Muñoz-Gomez J; Rivera-Fillat F; Ballesta AM
J Bone Miner Res; 1995 Mar; 10(3):458-65. PubMed ID: 7785468
[TBL] [Abstract][Full Text] [Related]
11. Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study.
Garnero P; Cloos P; Sornay-Rendu E; Qvist P; Delmas PD
J Bone Miner Res; 2002 May; 17(5):826-33. PubMed ID: 12009013
[TBL] [Abstract][Full Text] [Related]
12. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion.
Garnero P; Gineyts E; Arbault P; Christiansen C; Delmas PD
J Bone Miner Res; 1995 Apr; 10(4):641-9. PubMed ID: 7610936
[TBL] [Abstract][Full Text] [Related]
13. Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen.
Bonde M; Garnero P; Fledelius C; Qvist P; Delmas PD; Christiansen C
J Bone Miner Res; 1997 Jul; 12(7):1028-34. PubMed ID: 9200001
[TBL] [Abstract][Full Text] [Related]
14. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid.
Pectasides D; Nikolaou M; Farmakis D; Kanakis I; Gaglia A; Kountourakis P; Karamanos NK; Economopoulos T; Raptis SA
Anticancer Res; 2005; 25(2B):1457-63. PubMed ID: 15865105
[TBL] [Abstract][Full Text] [Related]
15. Prediction of the outcome of treatment of Paget's disease of bone with bisphosphonates from short-term changes in the rate of bone resorption.
Papapoulos SE; Frölich M
J Clin Endocrinol Metab; 1996 Nov; 81(11):3993-7. PubMed ID: 8923849
[TBL] [Abstract][Full Text] [Related]
16. The renal clearance of free and peptide-bound deoxypyridinoline: response to pamidronate treatment of Paget's disease.
Naylor KE; Jackson B; Eastell R
J Bone Miner Res; 2003 Apr; 18(4):658-61. PubMed ID: 12674326
[TBL] [Abstract][Full Text] [Related]
17. Comparison of biochemical markers of bone turnover in Paget disease treated with pamidronate and a proposed model for the relationships between measurements of the different forms of pyridinoline cross-links.
Randall AG; Kent GN; Garcia-Webb P; Bhagat CI; Pearce DJ; Gutteridge DH; Prince RL; Stewart G; Stuckey B; Will RK; Retallack RW; Price RI; Ward L
J Bone Miner Res; 1996 Aug; 11(8):1176-84. PubMed ID: 8854254
[TBL] [Abstract][Full Text] [Related]
18. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices.
Woitge HW; Pecherstorfer M; Li Y; Keck AV; Horn E; Ziegler R; Seibel MJ
J Bone Miner Res; 1999 May; 14(5):792-801. PubMed ID: 10320528
[TBL] [Abstract][Full Text] [Related]
19. Biochemical markers of bone turnover in Paget's disease of bone.
Delmas PD
J Bone Miner Res; 1999 Oct; 14 Suppl 2():66-9. PubMed ID: 10510216
[TBL] [Abstract][Full Text] [Related]
20. An immunoassay for measuring fragments of newly synthesized collagen type I produced during metastatic invasion of bone.
Cloos PA; Lyubimova N; Solberg H; Qvist P; Christiansen C; Byrjalsen I; Christgau S
Clin Lab; 2004; 50(5-6):279-89. PubMed ID: 15209436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
